Compare Intuitive Surgical, Inc. (ISRG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Intuitive Surgical, Inc. trades at $421.5 (market cap $149.10B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Intuitive Surgical, Inc. is far larger — about 19.8× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ISRG | SYRE | |
|---|---|---|
Market Cap | $149.10B | $7.52B |
Volume | 1,732,647 | 1,441,031 |
Sector | Health | Health |
52-Week High | $592.85 | $108.92 |
52-Week Low | $332.02 | $22.18 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $143.89B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $420.24, down 1.73% on the day, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The company reported $10.06B in 2025 revenue with 28.45% net margins, while technical indicators show a bullish trend with support at $414. Recent news highlights international expansion in India and Japan to offset China weakness.
ISRG presents a compelling investment case with 70% analyst buy ratings and a $480.78 price target offering 14% upside. Key risks include competitive pressures in robotic surgery and procedure growth concerns, but the company's market leadership and recurring revenue model support long-term growth prospects.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
